High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Cited by
Items 401–442 of 442
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610379
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610394
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944818
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610397
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944776
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944785
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944887
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944794
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944788
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944815
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944842
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944791
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944797
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944782
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944773
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610400
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944851
Conway, M. K., Xu, T., Kirkpatrick, A., Ripp, S. A., Sayler, G., & Close, D. (2020) · Figshare · doi:10.6084/m9.figshare.12610388
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944857
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944848
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944809
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944758
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944800
Ford, L. C., Lin, H.-C., Zhou, Y., Wright, F. A., Gombar, V. K., Sedykh, A., Shah, R., Chiu, W. A., & Rusyn, I. (2024) · Figshare · doi:10.6084/m9.figshare.26944881
Lautz, A. J., Kapcar, C. S., Zhang, S., Dunwoodie, L., Harmon, K., Mayhew, C. N., Atreya, M. R., Zingarelli, B., & Genomics of Pediatric Septic Shock Investigators (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.21.695853
Tantawy, M., Wang, D., Gbadamosi, M. O., Yu, F., Zhang, Y., Alomar, M., Shain, K. H., Baz, R., Bruno, K. A., & Yan, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031358
Self-citationHutschalik, T., Dasí, A., Riebel, L. L., Wiendels, M., Bakker, F., Beckers, L., Kriege, K. C., Valster, S. M., Vulders, R. C. M., Özgül, O. F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719392
Self-citationAmélioration de la régénération cellulaire et tissulaire au cours du vieillissement
Alle, Q. (2020) · theses.fr (ABES) · doi:10.70675/932e617bzcb45z4332z8badzfda37d5299a8
Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling
Guo, L., Rao, R., Liu, H. F., & Zhou, B. (2026) · Physiological Reports · doi:10.14814/phy2.70877
“In vitro, ponatinib induces toxicity in hiPSC-CFs and hiPSC-ECs (Sharma et al., 2017).”
Qiao, L., Xu, Y., Wang, X., Zhu, Y. C., Zhang, T., Niu, Y., Chen, M., Yang, S., & Liang, G. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05114-1
“…pathway and evaluating their maturity in drug response Complex organoid model containing cardiomyocytes, cardiac fibroblasts and endothelial cells [53] Found VEGFR2/PDGFR inhibition is a key pathway for TKIs to induce cardiotoxicity, and confirmed that up-regulation of insulin /IGF signaling…”
Sahu, P., Satapathy, A., Yadav, N., Satapathy, A., & Satapathy, T. (2026) · The Veterinary Journal Pharmacology & Toxicology · doi:10.1016/j.tvjpt.2026.100008
Jiang, F., Fu, H.-X., Wang, L., Pan, Z.-Z., Yan-qi, J., Liu, N., Chen, X., Gao, Z.-Z., Wu, W.-T., Yan, H., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01917-3
Li, Y., Zhang, Y., Sun, H., He, Y., Gao, D., Ding, T., Chen, X., Sun, Z., Jiang, S., & Dong, M. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10175-y
“Conversely, exogenous insulin or insulin-like growth factor 1 (IGF-1) upregulates cardioprotective signaling, thereby markedly improving the viability of human induced pluripotent stem cell–derived cardiomyocytes from cancer patients [81].”
Self-citationKuo, T.-Y., Cheng, M.-C., Jhou, H., LEE, C.-H., & CHEN, P.-H. (2026) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20612
New approach methodologies: drug screening platform to identify antifibrotic compounds
Zhang, H., Ren, L., Huang, R., Tan, R., Solow-Cordero, D. E., Mukherjee, S., & Wu, J. C. (2026) · Nature Protocols · doi:10.1038/s41596-026-01445-8
Self-citationClinical trials in a dish: cardiometabolic drug development with biological and digital twins
Patra, D., Sayed, I. M., Venkateshappa, R., Palaniappan, L. P., McLaughlin, T., & Wu, J. C. (2026) · Journal of Clinical Investigation · doi:10.1172/jci209668
“Advanced in vitro models can successfully unmask cell-intrinsic pathologies underlying lipid-induced hERG trafficking defects and mitochondrial bioenergetic collapse under drug challenge, which are broadly absent in preclinical animal screens (82–84).”
Self-citationHuman living myocardial slices as a new approach methodology
Koppers, L., Koutentaki, F., & Terracciano, C. M. (2026) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2026.100062
It Takes a Cell Village to Map Individual Cardiotoxicity Risk
Mergiotti, M., & Ghigo, A. (2026) · Circulation Research · doi:10.1161/circresaha.126.329601
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.